Published in Drug Week, October 10th, 2003
Martek Biosciences Kingstree Corp. has been formed as a wholly owned subsidiary of Martek Biosciences Corp. for the purpose of holding such assets and liabilities of FermPro.
"The addition of Martek Kingstree and its experienced workforce will add significant growth potential to the company's future production capacity," stated Henry "Pete" Linsert, Jr., chairman and CEO of Martek.
The purchase price of the assets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.